There are risks with anti VEGF shots ...and long term compliance is not that great
Anti-VEGF (anti-vascular endothelial growth factor) injections into the eye are commonly used to treat various retinal diseases like age-related macular degeneration, diabetic retinopathy, and retinal vein occlusions. While generally safe and effective, these injections can lead to certain complications:
Ocular Complications
Intraocular Inflammation/Endophthalmitis: There is a small risk of developing intraocular inflammation or endophthalmitis (severe intraocular bacterial infection) after the injection procedure.
Retinal Detachment/Tears: Intravitreal injections carry a risk of causing retinal tears or detachments, though the incidence is low.
Intraocular Hemorrhage: Subconjunctival hemorrhage can occur in around 10% of injections. Rare cases of massive subretinal or choroidal hemorrhages have also been reported.
Increased Intraocular Pressure (IOP): Studies show a significant portion (3.5-11%) of patients experience sustained IOP elevation after repeated anti-VEGF injections, potentially due to outflow obstruction or trabecular meshwork damage.
Silicone Oil Droplets: Silicone oil microdroplets can dislodge from the syringes used and accumulate in the vitreous, causing floaters and visual disturbances.
Systemic Complications
Thromboembolic Events: Though not conclusively proven, there are concerns that suppression of systemic VEGF levels by the injected anti-VEGF drugs could increase the risk of arterial thrombotic events like stroke or myocardial infarction.
Hypertension: Systemically administered anti-VEGF drugs are known to raise blood pressure by reducing vascular permeability. This risk with intravitreal injections is unclear.
While the overall safety profile is good, close monitoring for potential complications, especially IOP elevation, is recommended for patients receiving repeated anti-VEGF injections.
I think theres concern re repeat injections over time
Kiwi
Recent RZLT News
- Rezolute Announces Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement • GlobeNewswire Inc. • 06/27/2024 12:00:00 PM
- Rezolute Announces Closing of Public Offering with Approximately $60M in Gross Proceeds • GlobeNewswire Inc. • 06/24/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 08:51:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 06/14/2024 08:49:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 04:51:20 PM
- Rezolute Announces Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded Warrants • GlobeNewswire Inc. • 06/14/2024 03:30:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 06/13/2024 09:25:55 PM
- Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants • GlobeNewswire Inc. • 06/13/2024 08:01:00 PM
- Rezolute to Participate in the Jefferies Global Healthcare Conference • GlobeNewswire Inc. • 05/30/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/28/2024 06:56:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/24/2024 06:37:52 PM
- Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME) • GlobeNewswire Inc. • 05/21/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/17/2024 08:21:45 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 08:25:33 PM
- Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/15/2024 08:05:00 PM
- Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting • GlobeNewswire Inc. • 04/23/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/11/2024 09:03:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/11/2024 02:35:50 PM
- Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH) • GlobeNewswire Inc. • 03/06/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 01:47:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 10:00:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 04:55:02 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 10:00:07 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/13/2024 09:20:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2024 09:10:54 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM